MINDCURE moves an important step closer to the full commercial deployment of its iSTRYM digital therapeutics platform, and also makes a key addition to its management team.

Compass Pathways has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI), tracking the performance of NASDAQ biotechnology/pharmaceutical companies.

MindMed’s Phase IIa clinical trial of LSD for adults ADHD is officially underway, enrolling patients.

Awakn Life Sciences reports its Q3 for fiscal 2021. Highlights include key IP and clinic acquisitions, and the company’s first revenues.